Elderly Patients and Multiple Myeloma Treatment

This chapter explores the tailored treatment approaches for elderly patients with multiple myeloma, emphasizing the importance of age, comorbidities, and patient-specific health factors. It discusses significant findings from the AQUILA trial regarding treatment strategies for high-risk smoldering myeloma, highlighting the role of daratumumab in improving outcomes. Additionally, it addresses the implications of minimal residual disease (MRD) in clinical practice and emerging treatment methods that support better patient management.